Maintenance therapy in multiple myeloma
The treatment of multiple myeloma (MM) has changed dramatically in the past twenty years with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT) in younger patients and, more recently, of three novel agents (thalidomide, bortezomib, and lenalidomide). When conven...
Main Author: | Jean-Luc Harousseau |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2009-08-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/1105 |
Similar Items
-
Massive pleural effusion due to IgG multiple myeloma
by: Kathryn Jane Lang, et al.
Published: (2009-11-01) -
A Rare Case of Multiple Myeloma Presenting As Lytic Lesion of the Rib
by: DHRUVA SHARMA, et al.
Published: (2017-03-01) -
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
by: Alina Striha, et al.
Published: (2018-03-01) -
Management of Multiple Myeloma in Older Patients
by: Jian Li, et al.
Published: (2021-07-01) -
Tuberculosis of spine as the first clinical presentation of Multiple Myeloma: a case report
by: Zahra Ahmadinejad, et al.
Published: (2013-07-01)